Based on these preclinical findings, researchers conducted a multicenter phase I clinical trial to evaluated the safety, feasibility, and immunotherapeutic efficacy of mutant IDH1-targeted vaccination in newly diagnosed WHO grade III and grade IV glioma patients (24). This evidence concerns the gene IDH1 and central nervous system cancer.